Year archive

Enlivex Therapeutics Ltd. — 2021 filings

All 73 regulatory filings released by Enlivex Therapeutics Ltd. (ENLV) in 2021, sourced directly from the official regulator.

73 Filings

2021 Period

2021 filings (73)

Filing	Released	Lang
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece Regulatory Filings	2021-12-13	English
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece Report Publication Announcement	2021-12-13	English
Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece Regulatory Filings	2021-12-07	English
Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece Report Publication Announcement	2021-12-07	English
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra Regulatory Filings	2021-12-06	English
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra Report Publication Announcement	2021-12-06	English
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update Earnings Release Q3 2021	2021-11-22	English
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update Report Publication Announcement	2021-11-22	English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 Interim / Quarterly Report 9M 2021	2021-11-20	English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 Report Publication Announcement	2021-11-20	English
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain Regulatory Filings	2021-11-10	English
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain Report Publication Announcement	2021-11-10	English
Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain Regulatory Filings	2021-11-04	English
Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain Report Publication Announcement	2021-11-04	English
Immediate Report of Meeting -Technical Amendment AGM Information	2021-10-20	English
Enlivex Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells Regulatory Filings	2021-10-05	English
Enlivex Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells Report Publication Announcement	2021-10-05	English
Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis Regulatory Filings	2021-10-04	English
Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis Report Publication Announcement	2021-10-04	English
Immediate Report of Meeting AGM Information	2021-09-30	English
Immediate Report of Meeting AGM Information	2021-09-30	English
Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS Regulatory Filings	2021-09-22	English
Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS Report Publication Announcement	2021-09-22	English
After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients Regulatory Filings	2021-08-15	English
After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients Report Publication Announcement	2021-08-15	English
Announces Second Quarter 2021 Financial Results and Provides a Business Update Earnings Release Q2 2021	2021-08-09	English
Announces Second Quarter 2021 Financial Results and Provides a Business Update Report Publication Announcement	2021-08-09	English
FINANCIAL STATEMENTS JUNE 30, 2021 (UNAUDITED) -FORM 6-K Interim / Quarterly Report H1 2021	2021-08-07	English
FINANCIAL STATEMENTS JUNE 30, 2021 (UNAUDITED) -FORM 6-K Report Publication Announcement	2021-08-07	English
Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant Regulatory Filings	2021-08-02	English
Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant Report Publication Announcement	2021-08-02	English
Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant Regulatory Filings	2021-07-12	English
Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant Report Publication Announcement	2021-07-12	English
Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Ca Regulatory Filings	2021-06-15	English
Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Ca Report Publication Announcement	2021-06-15	English
FORM S-8-Registration Statement Regulatory Filings	2021-06-05	English
FORM S-8-Registration Statement Report Publication Announcement	2021-06-05	English
Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy Regulatory Filings	2021-06-01	English
Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy Report Publication Announcement	2021-06-01	English
Form 6-K-FIRST QUARTER 2021 RESULTS Interim / Quarterly Report Q1 2021	2021-05-29	English
Form 6-K-FIRST QUARTER 2021 RESULTS Report Publication Announcement	2021-05-29	English
Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Regulatory Filings	2021-05-18	English
Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Report Publication Announcement	2021-05-18	English
FORM 20-F FOR 2020 Annual Report FY 2020	2021-05-01	English
FORM 20-F FOR 2020 Report Publication Announcement	2021-05-01	English
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors Regulatory Filings	2021-03-22	English
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors Report Publication Announcement	2021-03-22	English
Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies Regulatory Filings	2021-03-08	English
Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies Report Publication Announcement	2021-03-08	English
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors Regulatory Filings	2021-03-01	English
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors Report Publication Announcement	2021-03-01	English
Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy Regulatory Filings	2021-02-22	English
Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy Report Publication Announcement	2021-02-22	English
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares Regulatory Filings	2021-02-18	English
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares Report Publication Announcement	2021-02-18	English
Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy Regulatory Filings	2021-02-16	English
Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy Report Publication Announcement	2021-02-16	English
6K-Amended and Restated Underwriting Agreement Regulatory Filings	2021-02-13	English
6K-Amended and Restated Underwriting Agreement Report Publication Announcement	2021-02-13	English
Prospectus Supplement to Prospectus dated June 21, 2019 Capital/Financing Update	2021-02-11	English
Prospectus Supplement to Prospectus dated June 21, 2019 Regulatory Filings	2021-02-11	English
Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares Capital/Financing Update	2021-02-10	English
Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares Report Publication Announcement	2021-02-10	English
POST-EFFECTIVE AMENDMENT TO FORM F-3-REGISTRATION STATEMENT Regulatory Filings	2021-02-10	English
POST-EFFECTIVE AMENDMENT TO FORM F-3-REGISTRATION STATEMENT Report Publication Announcement	2021-02-10	English
Announces $10 Million Bought Deal Offering of Ordinary Shares Capital/Financing Update	2021-02-10	English
Announces $10 Million Bought Deal Offering of Ordinary Shares Report Publication Announcement	2021-02-10	English
Prospectus Supplement to Prospectus dated June 21, 2019 Capital/Financing Update	2021-02-10	English
Prospectus Supplement to Prospectus dated June 21, 2019 Report Publication Announcement	2021-02-10	English
TERMINATION OF ATM AGREEMENT FROM 22.2.20 Regulatory Filings	2021-02-10	English
TERMINATION OF ATM AGREEMENT FROM 22.2.20 Report Publication Announcement	2021-02-10	English
Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program update Regulatory Filings	2021-02-03	English
Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program update Report Publication Announcement	2021-02-03	English

Filings by year

2026 45 filings
2025 63 filings
2024 69 filings
2023 55 filings
2022 62 filings
2021 73 filings
2020 78 filings
2019 40 filings